Literature DB >> 31646270

Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era.

Andrew J Krentz1, Robert Chilton2.   

Abstract

Entities:  

Year:  2018        PMID： 31646270      PMCID： PMC6739884          DOI： 10.1097/XCE.0000000000000150

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol Metab        ISSN： 2574-0954


× No keyword cloud information.
  10 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

Review 2.  8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018.

Authors: 
Journal:  Diabetes Care       Date:  2018-01       Impact factor: 19.112

3.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 4.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

5.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

Review 6.  Novel Diabetes Drugs and the Cardiovascular Specialist.

Authors:  Naveed Sattar; Mark C Petrie; Bernard Zinman; James L Januzzi
Journal:  J Am Coll Cardiol       Date:  2017-05-30       Impact factor: 24.094

Review 7.  After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Authors:  B Vergès; B Charbonnel
Journal:  Diabetes Metab       Date:  2017-04       Impact factor: 6.041

8.  Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?

Authors:  Muhammad Abdul-Ghani; Ralph A DeFronzo; Stefano Del Prato; Robert Chilton; Rajvir Singh; Robert E J Ryder
Journal:  Diabetes Care       Date:  2017-07       Impact factor: 19.112

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

Review 10.  SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Authors:  Naveed Sattar; James McLaren; Søren L Kristensen; David Preiss; John J McMurray
Journal:  Diabetologia       Date:  2016-04-25       Impact factor: 10.122
  10 in total
  1 in total

1.  Cardiometabolic medicine: time to recognize a new clinical specialty?

Authors:  Andrew J Krentz; Stephan Jacob
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-05-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.